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Abstract
Fournier’s gangrene (FG) is a rapid progressive bacterial 
infection that involves the subcutaneous fascia and 
part of the deep fascia but spares the muscle in the 
scrotal, perianal and perineal region. The incidence has 
increased dramatically, while the reported incidence of 
rectal cancer-induced FG is unknown but is extremely 
low. Pathophysiology and clinical presentation of rectal 
cancer-induced FG per se  does not differ from the other 
causes. Only rectal cancer-specific symptoms before 
presentation can lead to the diagnosis. The diagnosis of 
rectal cancer-induced FG should be excluded in every 
patient with blood on digital rectal examination, when 
urogenital and dermatological causes are excluded 
and when fever or sepsis of unknown origin is present 
with perianal symptomatology. Therapeutic options are 
more complex than for other forms of FG. First, the 
causative rectal tumor should be removed. The survival 
of patients with rectal cancer resection is reported as 
100%, while with colostomy it is 80%. The preferred 
method of rectal resection has not been defined. 
Second, oncological treatment should be administered 
but the timing should be adjusted to the resolution 
of the FG and sometimes for the healing of plastic 
reconstructive procedures that are commonly needed 
for the reconstruction of large perineal, scrotal and 
lower abdominal wall defects.
Key words: Fournier’s gangrene; Necrotizing fasciitis; 
Proctological examination; Necrotizing soft tissue 
infections; Oncological treatment; Rectal cancer; 
Surgical treatment; Reconstructive surgery
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in immunocompromised persons.
When referring to FG there are two important 
issues. First, it is important to define FG precisely 
because sometimes authors attribute other forms of 
infection to FG that require only simple drainage of 
pus and not extensive debridement[8]. In such cases, 
prognosis is excellent and the inclusion of these 
patients in the FG group leads to wrong conclusions. 
Second, diagnostic, therapeutic and prognostic 
parameters with longer follow-up should be written 
in future reports to have a complete picture of FG, 
especially rectal cancer-induced FG, which is extremely 
rarely published.
PUBMED AND GOOGLE SCHOLAR 
SEARCH
A Pubmed and Google Scholar search were conducted 
using the keywords “Fournier’s gangrene”, “necrotizing 
fasciitis”, “rectal cancer” and “rectal tumor”. Inclusion 
criteria were restricted to all case reports and case 
series in which the rectal cancer was confirmed as a 
cause of FG. Of the 27 articles dating from 1988 to 
2014, 23 were available as full-text and were relevant 
to our review.
INCIDENCE
The overall (reported) incidence of FG increased 
dramatically in the 20th century. From 1764 to 1978 
there were 386 reported cases and from 1950 to 
1999, 1726 cases[9]. The incidence is rising due to an 
increase in the mean age of the population, increased 
numbers of patients with comorbidities, widespread 
use of immunosuppressive therapy and those suffering 
from human immunodeficiency virus (HIV) infection, 
especially in Africa[10,11]. The overall incidence is 
1.6/100000 males and represents less than 0.02% 
of hospital admissions[10]. The real incidence could 
be underestimated because most cases with a grave 
prognosis were not published.
Anorectal causes
Anorectal pathology is the most common cause in 
both males and females (Table 1). The incidence 
varies significantly, mostly between 20% and 60% 
depending on the (sub)population analyzed. The most 
common causes are perianal/ischiorectal abscess and 
hemorrhoidectomy (Table 2). Other common causes 
are rectal injury and perianal fistula (Table 2); less 
common causes include sigmoid/rectal carcinoma, 
colorectal anastomotic dehiscence, appendicitis, 
perforated sigmoid diverticulitis, rectal biopsy, artificial 
sphincter or even anal dilation.
Rectal cancer-induced FG
The incidence of rectal cancer-induced FG is unknown. 
The first known case (of a famous person) with FG 
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Core tip: The reported incidence of Fournier’s gangrene 
(FG) has increased dramatically, while the reported 
incidence of rectal cancer-induced FG is unknown but is 
extremely low. Therapeutic options are more complex 
than for other forms of FG. First, the causative rectal 
tumor should be removed - survival with rectal cancer 
resection is reported as 100%, while with colostomy 
it is only 80%. Second, the timing of the oncological 
treatment should be adjusted to the resolution of 
the FG and sometimes for the healing of plastic 
reconstructive procedures commonly needed for the 
reconstruction of large perineal, scrotal and lower 
abdominal wall defects.
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INTRODUCTION
There has been confusion in the literature as to the 
precise definition of necrotizing fasciitis (NF) and 
Fournier’s gangrene (FG), which has been compounded 
by the use of multiple terms. Even although NF was 
actually first described by Hippocrates in the 5th 
century BC as a complication of erysipelas (many 
were attacked by the erysipelas all over the body 
when the exciting cause was a trivial accident flesh, 
sinews and bones fell away in large quantities, there 
were many deaths)[1], the description of the disease 
has been attributed by many to Avicenna (1025)[2] 
and Baurienne (1764)[3]. When NF involves the male 
genitalia, it is known as FG after Jean Alfred Fournier 
who described it in 1843 and Jones coined the term 
hospital gangrene in 1871[4]. In 1952, Wilson coined 
the term NF to describe the disease process that can 
occur in other parts of the body in either gender but 
which, when affecting the perineum, still merits the 
eponym FG[5].
Criteria for NF include: (1) fascial necrosis; (2) 
spreading cellulitis with undermining of fascial planes; 
and (3) systemic toxicity with altered mental state 
and hyperthermia. Some add (4) multiorgan failure 
as a criterion. NF is classified into four types. Type 1 is 
due to a mixture of aerobic and anaerobic organisms, 
usually following an abdominal or inguinal operation, 
or it is associated with diabetes mellitus. It is the 
most common, accounting for 80% or more of all the 
necrotizing soft tissue infections (NSTIs), including 
FG[6]. Type 2 is due to Group A Streptococcus infection 
synergistic with a second organism (Staphylococcus 
aureus, coliforms, Bacteroides spp.) observed in the 
limbs[7]. Type 3 stems from gram-negative marine 
bacteria. Type 4 is a fungal infection occurring mostly 
was that of Roman emperor Galerius. He suffered from 
diabetes and died of FG (in the advanced stage, worms 
were found in the perineal and scrotal area). Eusebius 
described the case and claimed that bowel cancer was 
the underlying cause[39]. Rectal cancer is the third most 
common cancer in the United States[40], with 40000 
patients diagnosed each year. Fortunately, there are 
several explanations for the low incidence of rectal 
cancer-induced FG. One is rectal cancer presentation 
before the potential development of FG and simple 
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Table 1  Anorectal causes of Fournier’s gangrene - incidence, colostomy rate, duration of hospitalization and survival
Ref. Anorectal 
cause
Male:female 
ratio
Rectal 
cancer in all-
cause group
Rectal cancer 
in anorectal 
cause group
Colostomy (all-
cause/rectal 
cause)
Survival (all-
cause/rectal 
cause)
The most 
common 
region
Duration of 
hospitalization 
(d)
Benjelloun el et al[12], 2013 70.00% 44:6 0% 10%/no data 76%/no data scrotum 21.00
Bhatnagar et al[13], 2008   7.30% Male only 
(110)
0% 4%/no data 92.7%/no data Scrotum 19.30
Cakmak et al[14], 2008 63.10% 45:20:00 0% 23.1%/no data 70.3%/no data 24.40
Carroll et al[15], 1986 50.00% 13:1 28.57%/no data 79%/no data 48.00
Czymek et al[16], 2009 57.60% 23:10 3%   5.26% 81.9%/no data
Efem[17], 1994   0.00% Male only (20) 0% Scrotum
Eke[9], 2000 21.00% 10:1 84%/no data 2-278
Eskitaşcıoğlu et al[18], 2014 20.00% 19:1      2.50% 50.00% 15%/no dana Scrotum 34.78
Fajdic et al[19], 2007 42.85% Male only (7) 0% 14.3%/no data 85.7%/no data Perianal 25.80
Ghnnam et al[20], 2008 54.05% Male only (74) 0% 1.4%/no data 78.4%/no data   9.20
Rodríguez Hermosa et al[21], 
2001
30.00% Male only (10) 0% 30%/50% 60%/75% Scrotum 27.00
Jiménez-Pacheco et al[22], 
2012
29.70% Male only (37) 0% 95%/no data 27.54
Kahramanca et al[23], 2014 22.06% 48:20      1.47%   6.67% 22.06%/no data 92.65%/no data 15.37
Kara et al[24], 2009 33.30% 10:5 0% 53.3%/no data 80%/no data Scrotum and 
perineum
Karbhari et al[25], 2014 20.00% 0% 80%/no data Scrotum
Khan[26], 2009 21.00% Male only (19) 0% 5.3%/no data 26.00
Khandelwal[27], 2013 24.60% Male only (57) 0% 20.3%/no data 68.5%/no data 19.60
Korkut et al[28], 2003 58.00% 37:8      2.22%   3.85% 40%/no data 80%/no data 12.00
Liang et al[29], 2008 87.50% Female only 
(8)
0% 87.5%/85.7% 75%/85.7% 32.20
Morua et al[30], 2009 48:2 10%/no data 88%/no data Scrotum 23.76
Table 2  Anorectal causes of Fournier’s gangrene
Ref. Abscess Hemorrhoidectomy Hemorrhoids Intestinal 
obstruction
Perianal 
fistula
RT for rectal 
carcinoma
Rectal 
carcinoma
Artificial 
sphincter
Anal 
fissure
Rectal 
injury
Benjelloun el et al[12], 2013   88.50% 11.50%
Bhatnagar et al[13], 2008 75.00% 25.00%
Cakmak et al[14], 2008   43.90% 43.90% 12.20%
Czymek et al[16], 2009   68.42%   3.00% 15.79%     3.00% 3.00%
Eskitaşcıoğlu et al[18], 2014   56.25% 12.50%   12.50% 18.75%
Fajdic et al[19], 2007   33.30% 33.30% 33.30%
Ghnnam et al[20], 2008   90.00% 10.00%
Rodríguez Hermosa et al[21], 
2001
  75.00% 25.00%
Kahramanca et al[23], 2014   66.66%     6.66% 26.66%
Kara et al[24], 2009   60.00% 40.00%
Khan[26], 2009   75.00% 25.00%
Khandelwal[27], 2013   75.00% 25.00%
Korkut et al[28], 2003   92.30% 4.16%     4.16%
Liang et al[29], 2008 100.00%
Oymacı et al[31], 2014 100.00%
Ozkan et al[32], 2014   62.50%   25.00% 12.50%
Singh et al[33], 2004 100.00%
Tan et al[34], 2006   40.00% 40.00%   20.00%
Unalp et al[35], 2008 100.00%
Villanueva-Sáenz et al[36], 2002   88.00% 8.00%     4.00%
Walker et al[37], 1983 100.00%
Wang et al[38], 2012   91.00%     9.00%
RT: Radiotherapy.
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these, 5.8% are located in the rectum[70]. In 1977, 
50% of perforated colorectal cancers were at the 
rectosigmoid junction[71]. The site of perforation of 
the primary colorectal tumor is related to the primary 
tumor site in 50%[72]. One should be cautious with 
interpretation because ulceration at the site of a 
primary tumor (with or without chemoradiotherapy) 
may be a non-specific finding as ulceration and 
deep necrosis are typical features in malignancies 
overall. Rectal cancer perforation as an adverse effect 
of preoperative (chemo)radiotherapy is extremely 
rare[73,74]. With increased use of bevacizumab, a 
monoclonal immunoglobulin G1 antibody directed 
against VEGF, gastrointestinal perforation as a side 
effect was observed in 1.7% of patients. Only 4.2% 
of these were from the rectal cancer[75]. In a study 
by Hurwitz et al[76], the gastrointestinal perforation 
rate was 1.5% in the group with previously untreated 
metastatic colorectal cancer. There are no data about 
the perforation site. 
PATHOPHySIOLOGy
FG exists due to synergism between low aggressive 
multiple aerobic and anaerobic organisms that are 
normally present within the distal rectum and perianal 
area. Aerobes cause platelet aggregation, accelerate 
coagulation by fixing complement and produce 
heparinase[77]. The presence of sialic acids on the cell 
walls of the Streptococcus spp. and Escherichia coli 
(E. coli) helps to inactivate the alternate complement 
pathway[78]. microthrombosis of nutrient vessels 
reduces local blood supply, causing dermal necrosis, 
and allows the growth of facultative anaerobes and 
microaerophilic organisms such as E. coli. Bacteroides 
spp. that inhibits phagocytosis of many aerobes[79]. 
These produce the relatively insoluble gases composed 
of hydrogen, hydrogen sulphide, nitrogen and nitrous 
oxide, causing subcutaneous gas collections. Whether 
subcutaneous emphysema is merely the manifestation 
of a perforated rectal cancer or from bacterial gas 
production can be difficult to determine. The syner-
gistic activity of aerobes and anaerobes leads to the 
production of various exotoxins and enzymes like 
collagenase, heparinase, hyaluronidase, streptokinase 
and streptodornase. This leads to digestion of 
fascial barriers, thus fueling the rapid spread of the 
infection and hemolytic anemia due to streptococcal 
hemolysins[78,80]. It does not appear that the origin of 
the infection (rectum, urinary, dermal) has any impact 
on the specificity of the species cultivated[68]. 
Urogenital origin
The infection originates from the urogenital triangle, 
usually secondary to urethral instrumentation. If 
the source is penile, then after the tough fibrous 
tunica albuginea is penetrated, the infection spreads 
to involve Buck’s fascia[81] which initially limits the 
diagnosis. When the upper rectum is involved, 
patients can present with bowel obstruction before the 
potential development of FG. In addition, up to 26% 
of obstructive large bowel perforations are proximal 
to the obstructing (non-perforating) tumor, presenting 
as acute abdomen, not FG. In addition, screening 
programs result in earlier stage rectal cancer diagnosis. 
We collected 23 cases with proven rectal cancer-
induced FG (Table 3), although there are several more 
published[64] which were unavailable for analysis. The 
average age of patients with rectal cancer-induced 
FG was 60 years (range 28-80) with a male: female 
ratio of 21:2. The incidence of rectal cancer-induced 
FG in all-cause FG ranged from 1.47% to 16.6% and 
in the anorectal group varied significantly from 3.85% 
to 100% (Table 1). These percentages should be 
interpreted with caution because the studies included 
different etiological groups of patients.
RISk fACTORS
All-cause FG
Predisposing factors for all-cause FG are poor perfusion 
(peripheral vascular disease), hypertension, renal 
insufficiency, trauma, diabetes mellitus, malnutrition, 
smoking, obesity, immunocompromised status, 
intravenous drug abuse, malignancy and spinal cord 
injury[1]. Alcoholism and diabetes mellitus are the most 
common in western countries, with rates of 25%-50% 
and 10%-60%, respectively[65-68]. Old age is not a 
predisposing factor; however, elderly patients with 
poor self-care and poor nutritional status are more 
susceptible[1]. Female to male ratio varies significantly 
(Table 1). The lower incidence in women is ascribed to 
better drainage of the perineal region through vaginal 
secretions[9,43]. In addition, the reported ratio depends 
on the type of clinic in which the data are collected, 
namely urology, surgery or gynecology. Reports from 
urology clinics tend to contain fewer female patients, 
while the incidence of females is higher in reports from 
general surgery clinics.
Anorectal causes of FG
From the published data, it is not possible to define 
specific risk factors for this group. General risk factors 
could be applied here. The proportion of anorectal 
causes ranges from 0% to 92.6% (average 40%) 
(Table 1).
Rectal cancer-induced FG
Seven of 23 articles (Table 3) mentioned general 
risk factors for rectal cancer-induced FG; the most 
common being diabetes mellitus. A specific risk factor 
is rectal cancer perforation. The risk of rectal cancer 
perforation besides its growth is neoadjuvant or 
therapeutic chemoradiotherapy. Colorectal carcinoma 
constitutes 9.2% of all colorectal perforations[69]. 
Of all colorectal carcinomas, 5.9% perforate and of 
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buttocks and thighs.
There are three different etiopathogenetic paths 
of infection with rectal perforation. First is iatrogenic 
retroperitoneal rectal perforation without the pre-
sence of rectal carcinoma. This mechanism is found 
during rectal instrumentations, barium enemas and 
diagnostic/therapeutic colonoscopy. The second 
mechanism is external rectal trauma sometimes with a 
foreign body retained through the rectal wall. The third 
mechanism is true spontaneous perforation of rectal 
cancer that can develop into two clinical forms. more 
commonly it presents as ischiorectal and/or gluteal 
abscess or rarely in a form of FG. Tumor infiltration (with 
or without necrosis) of the rectal wall and surrounding 
tissues spreads the infection. Infection is much more 
fulminant then in iatrogenic extraperitoneal rectal 
perforation[86-88]. This is due to pre-procedural bowel 
preparation with or without prophylactic antibiotics 
which significantly reduces the incidence and severity 
of the infection.
Whatever the cause of FG, testicular involvement is 
rare because of the separate blood supply to the testes 
and the testicles are always spared if the disease 
affects the subcutaneous tissue only[89]. If necrotic 
testicles are found, an intra-abdominal process which 
leads to thrombosis of the testicular artery should be 
strongly suspected[45]. 
CLINICAL PRESENTATION
Local findings
It is difficult to determine the exact time point at which 
the disease progresses from a primary infection to an 
FG. Clinical presentation of perianal or scrotal FG has 
many similarities. When the disease progresses slowly, 
patients are often unable to remember a specific date 
of symptom onset or sometimes report a date more 
recent than the actual date. In this way, they attempt 
to avoid giving the impression that they were reluctant 
to seek medical help or that they underestimated 
their disease. most patients seek medical attention an 
average of 5 d after the onset of symptoms[65]. Where 
mentioned in rectal cancer-induced FG, the duration of 
symptoms lasted 2-14 d (Table 3).
The course of the disease can be divided into 
two phases that are characterized by different rates 
of disease progression. A first phase, stable and 
sometimes long, during which the body’s immune 
system prevents local inflammation from spreading, 
is followed by a second phase during which infection 
progresses rapidly to the fulminant illness. It begins 
with a prodromal period of genital discomfort and 
pruritus followed by sudden onset of perianal or perineal 
pain out of proportion to the physical findings[1]. As the 
FG progresses, the pain is replaced by numbness and 
subsequent anesthesia caused by damage to cutaneous 
nerves[90]. Irrespective of the bacterial species, the 
initial bacterial growth takes place in the subcutaneous 
tissues, i.e., the subcutaneous fat, superficial fascia 
and the superficial layer of the deep fascia. The skin 
remains intact initially and the extent of the subdermal 
gangrene may not be apparent[91]. Later, skin develops 
patchy necrosis and becomes gangrenous. The swollen, 
shiny scrotum skin is a typical early symptom of scrotal 
infection. Due to a lack of subcutaneous fat in the 
scrotum, necrosis of dartos fascia leads to exposure 
of the testes that may be coated with a thick layer 
of creamy pus. Sometimes small skin ulcers drain 
thin, reddish-brown, foul-smelling fluid (“dishwater 
fluid”). An odor characteristic of anaerobic infection 
may be present. Surrounding these draining wounds 
are variable amounts of skin necrosis. Induration or 
distinct margins are absent, with the diseased area 
gradually fading into normal skin. A black spot or dusky 
area in the perineal skin surrounded by erythema 
is considered pathognomonic of FG[61]. Crepitus and 
subcutaneous gas (gaseous emphysema) indicate the 
presence of dead tissue[92]. Crepitus in all-cause FG is 
found in 19%-64% of patients[93,94] and depends on 
the duration of FG and the underlying cause. There 
are no data about the incidence of crepitus in rectal 
cancer-induced FG. It commonly occurs in the first 
48-72 h[95-97]. Some patients have blisters and bullas 
of adjacent tissues, initially filled with serous and then 
hemorrhagic fluid[98-100]. Lymphangitis and lymphadenitis 
are rare[101,102]. FG progresses at the speed of 2-3 
cm2/h[36,103].
Initial localization of pain, edema and redness could 
lead to the underlying group of etiologies. If the initial 
presentation involves scrotum and penis or only penis, 
urogenital pathology could be the cause[17]. All-cause 
FG starts as scrotal edema (Table 1) and therefore a 
group of causes cannot be defined only due to scrotal 
edema. Gangrene extension to the perineal/perianal 
region in delayed presentation complicates the 
possibility of identification of the cause. The scrotum 
should be checked for generalized crepitus, edema, 
erythema, tenderness, superficial ulcerations, odor 
and discharge. Both testicles should be palpated and 
compared. The penis should be checked for lesions 
and discharge. The patients should be asked about 
recent urinary catheterization. Prostate infiltration by 
the rectal tumor can present with prostatic symptoms 
and can be misleading.
The most common initial localization of rectal 
cancer-induced FG is the scrotum (Table 3). When 
scrotal edema develops in patients with anorectal pain, 
rectal bleeding, tenesmus or alteration of bowel habits 
and unintentional weight loss, rectal cancer should 
be suspected. Cachexia, weight loss, anemia, rectal 
bleeding, constipation and diarrhea were present in 
this group (Table 3). Urinary retention was present in 
one patient. There are several mechanisms and risk 
factors for this presentation. Old age is a risk factor 
for urinary retention and benign prostatic hyperplasia. 
Also perianal/perineal pain plus infection that disturbs 
sympathetic and parasympathetic neuronal pathways 
in the surrounding area causes urinary retention that 
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can mislead to the conclusion of the urogenital origin 
of FG.
Systemic findings
Systemic findings can also be misleading. Patients may 
have a fever, malaise for a few days[104], nonspecific 
abdominal pain[105] and general symptoms of infection 
without symptoms from the perineal area[106,107]. The 
septic state develops with the rapid development 
of severe toxemia, causing pyrexia with or without 
hypothermia, tachycardia, hypotension and reduced 
urine output[90]. Sepsis may occur in just a few hours, 
progressing to organ failure and death[90]. The clinical 
picture is similar regardless of the bacterial species 
involved. All patients with fever or sepsis of unknown 
origin require a thorough genital, perineal and 
proctological examination.
DIffERENTIAL DIAGNOSIS
Differential diagnosis includes two groups of diseases. 
The first group consists of other forms of NSTIs, also 
called infectious gangrene or gangrenous cellulitides 
(Table 4[91,108-111]), and the other consists of diseases 
that resemble gangrenous/necrotic infections. These 
are not progressive bacterial infections but rather 
presentations of systemic or localized diseases or an 
immunocompromized host.
DIAGNOSIS
FG per se
The diagnosis is usually a clinical one. Early clinical 
recognition of FG is difficult as the disease is often 
indistinguishable from cellulitides/abscesses early 
in its evolution (Table 4). To aid in diagnosis, a risk 
score was developed - the Laboratory Risk Indicator 
for Necrotizing Fasciitis (LRINEC) score. A score of 
≥ 6 raises the suspicion of NF and a score of ≥ 8 is 
strongly predictive of the disease.
Laboratory findings define the disease severity, 
septic state and metabolic derangements. A full blood 
count, C-reactive protein (CRP), urea, creatinine, 
glucose, calcium, potassium, sodium, coagulation 
studies, fibrinogen/fibrin degradation product levels 
and acid-base status should be checked. Diabetics 
may present with ketoacidosis[112]. A mid-stream urine 
sample excludes/confirms urinary tract infection. One 
should be cautious because it can also be present 
despite a causative rectal tumor. Hypocalcemia 
due to bacterial lipase is an important indicator of 
the early stage[113] and develops from extensive 
fat necrosis[114]. Total protein and albumin levels 
show obligatory hypoalbuminemia, especially in the 
advanced presentation. Full blood count, calcium and 
CEA marker are rarely mentioned in articles with rectal 
cancer-induced FG. CRP was noted in 26% of these 
cases and ranged from 149 to 424 mg/L (Table 3). 
Leukocytes were noted in 57% with a range of 10000/
mm3-36800/mm3 with one patient with 2700 mm3 due 
to sepsis (Table 3).
The following two clinical courses should increase 
the likelihood of FG: (1) an infectious process that 
does not respond well to antibiotics; and (2) septic 
symptoms disproportionate to scrotal cutaneous 
manifestations in the early stage of infection[3].
The finger test is diagnostic. This is a bedside 
procedure where under local anesthesia a 2 cm 
incision is made over most prominent cutaneous 
changes down to the deep fascia and a gentle probing 
maneuver with the index finger is performed at the 
level of the deep fascia. The lack of bleeding, presence 
of characteristic dishwater pus and easy blunt finger 
dissection of subcutaneous tissue off the fascia are 
features of a positive test[115].
Tissue biopsies and pus (during finger test and 
intraoperatively) define causative microorganisms and 
possible underlying pathology. The histopathological 
features of FG are necrosis of the superficial fascia 
with blood vessel thrombosis and suppuration[101,116]. 
Other consistent features include severe subcutaneous 
fat necrosis, severe inflammation of the dermis and 
subcutaneous fat, vasculitis, often with endarteritis, 
and local hemorrhage[101,116]. In the early stage, the 
epidermis shows no major changes[116].
Underlying cause
Digital rectal examination was performed in 70% of 
rectal cancer-induced FG cases and was positive in 
75%, performed mostly preoperatively (Table 3). 
microperforation can be confirmed or ruled out in 
palpable tumors. Impalpable perforation does not 
exclude microperforation.
Rectoscopy (as a bedside or intraoperative 
procedure) is mandatory in the following situations: 
(1) blood (any form) on digital rectal examination; 
(2) history and other/previous diagnostic modalities 
that refer to rectal carcinoma; (3) urogenital and 
dermatological causes have been excluded; (4) bacteria 
highly specific for (intestinal) rectal malignancy such 
as Clostridium septicum[117]; and (5) fever or sepsis 
of unknown origin with perianal symptoms/signs. 
Rectoscopy was performed in 52% of rectal cancer-
induced FG with equal frequency preoperatively and 
during the initial operation (Table 3).
Gas may be detected on plain X-ray, indicating the 
presence of dead tissue[92]. X-rays were done in only 
13% of rectal cancer-induced FG (Table 3).
Gas within the scrotal wall on ultrasound may 
be seen prior to clinical crepitus. Reactive unilateral 
or bilateral hydroceles may be present. If testicular 
involvement occurs, there is likely an intra-abdominal 
or retroperitoneal source of infection. Ultrasound is 
also useful in differentiating FG from incarcerated 
inguinoscrotal hernia, the data unknown for rectal 
cancer-induced FG.
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Bruketa T et al . Rectal cancer and Fournier's gangrene
TREATMENT
Proctological examination under general anesthesia 
identifies the cause of the disease and determines its 
extent. A proposed diagnostic/therapeutic algorithm 
for rectal cancer-induced FG is presented in Figure 1.
Rectal cancer treatment modalities 
Colostomy: Colostomy has been used for fecal 
diversion in cases of severe perineal involvement in 
all-cause FG with: (1) anal sphincter involvement; 
(2) fecal incontinence; and (3) continuous fecal 
contamination of the wound’s margins.
Rectal diversion decreases the number of germs 
in the perineal region and improves wound healing. 
The primary colostomy rate is 16%-17%, whereas the 
secondary colostomy rate is 35%-40%[119,120]. In an 
anorectal female group, colostomy rate was 83.7%, 
with a primary colostomy in 37.5% and a secondary 
colostomy in 50%[29]. Colostomy rate in the anorectal 
group varies from 50% to 100% (only four articles 
have adequate data) (Table 1). 
A transverse loop colostomy is preferred because it 
yields solid and formed stools with little contamination 
of the surrounding skin. The abdomen above the 
umbilicus is ideal because FG often extends into the 
lower abdominal wall[121]. Necrosis around the stoma 
causes stomal detachment necessitating stomal 
translocation. In addition, colostomy should not be 
brought through the rectus muscle until the plastic 
surgery team has selected the possible reconstructive 
option. most commonly, the vertical rectus abdominis 
myocutaneous flap (VRAm) with skin from the 
supraumbilical area provides excellent soft tissue 
bulk to obliterate perineal dead space[122-124]. Stool 
and urinary diversion ostomies can be brought out 
through one rectus muscle only after elevation of the 
contralateral VRAm[125].
Colostomy, as the only (mentioned) treatment 
of rectal cancer-induced FG, was performed in 43% 
of cases, with mortality of 20%. Three important 
parameters from published articles are not known: (1) 
rectal cancer operability and whether the colostomy 
was definitive surgical treatment; (2) long-term follow-
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Figure 1  Diagnostic-therapeutic algorithm for suspected/proven Fournier’s gangrene due to rectal cancer. Perioperative management and necrosectomy are 
excluded which are standard procedures in Fournier’s gangrene treatment in all patients. 1Impalpable perforation does not exclude microperforation; 2(1) Blood (any 
form) on digital rectal examination; (2) history and other/previous diagnostic modalities refer to rectal carcinoma; (3) urogenital and dermatological causes excluded; 
(4) bacteria highly specific for (intestinal) rectal malignancy such as Clostridium septicum; and (5) fever or sepsis of unknown origin with perianal symptoms/signs; 
3Increased soft tissue density with abscess and/or gas bubbles around the tumor; 4After confirmation of rectal cancer, definitive oncological operation is performed 
after stabilization and neoadjuvant chemoradiotherapy if indicated. Reconstructive surgery after consultation with plastic surgeon.
Fournier’s gangrene  with 
suspected rectal cancer
Preoperative or intraoperative
rectoscopy2
Digital rectal examination
Non-perforated tumor1Perforated tumor Negative
Abdominopelvic CT scan
Confirmation/suspicion of
rectal cancer perforation3
Fournier's gangrene not
due to rectal cancer
Transversostomy/sigmoidostomy
Hartmann's procedure
(Extralevator) 
abdominoperineal resection
Unstable patient
Stable patient
Stabilization4
±
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up and therefore additional procedures that could be 
performed at later date are unknown; and (3) the 
location of the colostomy.
The therapeutic algorithm is not defined if rectal 
cancer infiltrates the prostate. Should colostomy be 
made first, followed by chemoradiotherapy and as 
a final act abdominoperineal resection (APR)[50], or 
should the APR be made as the first and definitive 
operation? If a patient presents with multiple bilobar 
liver metastases colostomy could be the first line 
therapy.
Rectal diversion device(s): The Flexi-Seal® Fecal 
management System by Convatec is a silicone catheter 
that protects the wounds from fecal contamination. 
It is an excellent alternative to colostomy for a 
shorter period (several weeks). The device avoids 
complications related to stomas, including better 
psychological recovery, and may have an economic 
benefit. Unfortunately, recommendations from the 
manufacturer contraindicate its use when (perforated) 
rectal cancer with FG or any anorectal cause with 
FG is present[126]. On the contrary, Ozkan et al[32] 
recommended its use in FG with excellent results.
Rectal cancer resection: Rectal carcinoma is 
different from most other, even anorectal, causes of 
FG because elimination of systemic risk factors and 
purulent collection(s) does not eliminate the source of 
infection. Perforation of rectal cancer per se produces 
infection; therefore, resection of the perforated rectal 
tumor is mandatory (see Prognosis). If the tumor did 
not perforate, other causes should be ruled out. In this 
situation, initial resection of the rectal cancer is not 
mandatory. The most experienced surgeon available 
should perform the operation.
Localization of rectal cancer was described as 
the lower or upper rectum (imprecise localization) in 
13% and distance from the anocutaneous line was 
noted in 30%, ranging from the anocutaneous line 
to 10 cm (Table 3). APR as the initial operation was 
performed in 13% of cases; colostomy as an initial 
procedure with delayed APR in 26% of cases (Table 3). 
The latter option could be for the patients with poor 
operative risk, presence of the septicemia, old age 
or hemodynamically unstable patients. These factors 
eliminate the possibility of an aggressive approach 
and at the first instance, necrotic and infected 
tissue is removed and major surgery postponed 
until the patient’s condition improves[46]. There are 
two advantages to this approach: (1) subsequent 
colonoscopy with pathohistological diagnosis of the 
rectal tumor; and (2) detection of synchronous 
colorectal tumors, eliminating the need for subsequent 
resections. Unfortunately, when rectal cancer-induced 
FG is present, a delay of up to 7 d is intolerable due 
to the rapid progression of FG and the need for rapid 
elimination of the infective source. The patients should 
be warned about possibility of permanent stoma.
In high rectal cancers, the dilemma is whether to 
do anterior rectal resection, Hartmann’s procedure or 
APR. Hartmann’s procedure adds safety due to fecal 
diversion and was performed in 8.7% of cases as 
primary treatment (Table 3). The problem could be the 
revascularization of the rectal stump due to extensive 
debridement of the perirectal area. Therefore, even 
in high rectal cancer associated with FG, APR has the 
advantage of eliminating all infective focuses in the 
perineal/perianal region. The perineum is not closed 
primarily but packed with several gauze rolls. When 
the spread of FG is stopped and the hemostasis is 
achieved with packs, then vacuum assisted closure 
(VAC) minimizes skin defects and speeds tissue 
healing. The location of the perineal wound makes 
it difficult to maintain an adequate seal due to the 
irregular surfaces surrounding the gluteal folds and 
perineum. Enemas could be applied before changing 
the VAC dressings in patients without a diverting 
colostomy. VAC dressings are changed every 72 h or 
when the progression of gangrene is found. Ozkan et 
al[32] recommend a lower limit of pressure (without 
explanation) which was originally recommended to be 
between 50 and 125 mmHg.
Currently, extralevator APR (eAPR) is recommended 
for elective low rectal cancers[127]. It consists of wider 
excisions with en bloc resection of the distal rectum, 
sphincter complex and levator muscles, resulting in a 
cylindrical specimen. This reduces the rate of positive 
resection margins and tumor perforation in distal rectal 
cancer and improves oncological outcome, especially 
in perforated forms, as in FG. Wider excisions and 
increased use of neoadjuvant chemoradiotherapy 
have significantly increased perineal wound healing 
problems, in up to 59%[128,129]. Furthermore, perineal 
hernia is more likely - found in up to 20%[130]. Clinical 
outcome of biological meshes during eAPR appeared 
comparable to flap assisted perineal closure in a non-
randomized studies based on a systematic review[131]. 
Perineal hernias after biological mesh closure following 
eAPR were 8.2%[130,132-135]. One of the assumptions for 
successful use in FG is that gangrene (mostly) does 
not affect muscles; therefore, mesh can be securely 
sutured to the muscles surrounding the defect after 
eAPR. The unsolved issue is the timing of application of 
biological mesh in FG patients.
Extensive debridement
Current estimates of all-cause FG mortality are 21% 
(range 7% to 75%), similar to 22% mortality from the 
pre-antibiotic era[136]. This suggests that initial therapy 
needs to be more aggressive and the first operation 
more extensive and definite. This also suggests that 
antibiotic therapy is not the main therapy. If in doubt, 
cut it out is a truism in FG[61]. Intraoperative lack 
of resistance of normally adherent fascia to blunt 
dissection is confirmation of NF[7,114]. Debridement 
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should be stopped when the separation of the skin 
and the subcutaneous tissue is not performed easily 
because the cutaneous necrosis is not a good marker. 
Surgical reexamination of the infected area and 
detachment of the necrotic tissue is advocated within 
24 h and should be carried out repeatedly. In all-
cause FG, an average of 3.5 procedures is required[137]. 
most studies on anorectal etiology declare multiple 
procedures without absolute numbers. This is also 
true for rectal cancer-induced FG (Table 3). Duration 
of hospitalization is unknown for the anorectal group. 
Duration of hospitalization for the rectal cancer-
induced FG was noted in 30% of cases, with a range of 
23-130 (average 47) d.
The crucial significance of testicular infarction, 
implying thrombosis of the testicular artery, must be 
recognized as an absolute indication for laparotomy 
and retroperitoneal exploration. The posterior 
peritoneum may need to be incised before necrotic 
retroperitoneal tissues are exposed.
Hemorrhage or perioperative blood loss is inevitable 
due to: (1) extensive debridement; (2) possible DIC; 
and (3) rectal resection. In addition, microcytic anemia 
can be present preoperatively due to a bleeding rectal 
tumor.
Antibiotic therapy
The optimal approach to empiric antibiotic therapy for 
FG is uncertain; data are limited since most clinical 
trials exclude FG patients. The optimal duration of 
antibiotic treatment has not been defined. Antibiotics 
should be continued until no further debridements 
are needed and the patient’s hemodynamic status 
and temperature has normalized; this duration must 
be tailored to individual patient circumstances or 
laboratory parameters such as leukocyte count or 
CRP level. High intravenous doses should be used. 
Antibiotics should be adjusted to culture results. 
most common initial (empiric) combinations used 
for all-cause FG are: (1) penicillin G or ampicillin, 
aminoglycoside or 3rd generation cephalosporin plus 
metronidazole or clindamycin[138]; (2) benzylpenicillin 
plus clindamycin plus gentamicin. If penicillin-allergic, 
meropenem plus clindamycin plus gentamicin. Review 
the need for gentamicin daily[139]; (3) meropenem plus 
clindamycin[140]; (4) clindamycin plus ciprofloxacin plus 
metronidazole[141]; and (5) for suspected Vibrio spp. 
include a tetracycline and 3rd generation cephalosporin 
(e.g., doxycycline plus ceftazidime), ciprofloxacin may 
be an alternative[142,143].
Nutritional support
Due to extensive debridement, physiological changes 
are similar to extensive and deep burns. Patients with 
infected wounds or sepsis have increased requirements 
for nutrients and often have a reduced food intake. 
Early nutritional support had a significantly shorter 
duration before split thickness skin grafting than 
the conventional support[144]. The catabolic effect of 
primary malignancy and/or cachexia could be present.
A nasogastric tube is placed when mechanical 
ventilation is required and when patients are unable to 
eat a satisfactory diet. Total parenteral nutrition (TPN) 
is used only if patients are unable to be fed enterally. 
Enteral nutrition is provided with high protein formulas. 
Attempts to estimate nutrient requirements based 
on any formula will inevitably lead to over- or under-
feeding. Indirect calorimetry (IC) remains the most 
precise method to determine energy requirements. 
When IC is not available, provide calories at 25 
kcal/kg per day or about 124% of estimated basal 
needs[145,146]. Energy expenditure should be measured 
by IC 2-3 times a week. Respiratory therapists 
measure oxygen consumption, production and resting 
energy expenditure and respiratory quotient in the 
early morning before patients began daily activities. 
Due to their clinical status (i.e., symptoms consistent 
with sepsis syndrome), patients are generally sedated, 
intubated and receiving analgesics during IC. Resting 
energy expenditure is recorded when measurements 
are stable for at least 10 min. Patients on TEN or TPN 
had feedings continued at a steady rate throughout 
each measurement; patients on oral diets are measured 
before breakfast after an overnight fast.
Adjunctive therapy
Underlying risk factors and metabolic derangements 
should be corrected. Honey, royal jelly, hyperbaric 
oxygen therapy, sodium hypochlorite, lyophilized 
collagenase, growth hormones, protein synthesis 
inhibitors and intravenous immunoglobulins are all 
adjunctive methods but without definitive proof of their 
positive therapeutic effect.
Reconstructive surgery
There are two main timing options for reconstructive 
surgery: (1) at the time of initial admission[21]; or 
(2) after the acute process has fully resolved. Recon-
structive surgery is considered when an extensive 
healthy granulation tissue formation on the wound 
base is present. Secondary healing or delayed 
primary closure is applied for small residual defects 
(< 10 cm2)[16]. Eventually, testes can be covered 
with remaining scrotal skin or implanted in the 
subcutaneous tissue of the thigh or abdomen if viable.
To improve healing of the large perineal wound, 
sutured perineal pedicled retrocolic omentoplasty can 
be added to the procedure of APR[147,148]. The great 
omentum is pediculized on the left gastroepiploic artery 
and tightly sewn to the subcutaneous fatty tissue of 
the perianal skin. Although a high level of evidence 
is lacking, the procedure adds well vascularized, 
non-irradiated tissue to the pelvic cavity[149]. The 
well-vascularized muscle flap demonstrates greater 
resistance to bacterial inoculums and in wounds with 
some degree of contamination[150]. In the only study 
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with follow-up of all-cause FG during the first 12 mo 
after hospital discharge, 12% of patients required 
inpatient hospital treatment for fistulas and needed 
revision surgery for new inflammatory processes[16]. In 
elective settings, after APR, VRAM and gluteal flap have 
been used for closure of large perineal defects[123,151-153]. 
The problem arises when large areas are debrided, 
eliminating the possibility for the use of standard flaps. 
In addition, if adjuvant chemoradiotherapy is indicated, 
the questions are: (1) should the flaps be used; and (2) 
the timing of flap application. Also, due to the donor 
site morbidity, increased operative time and higher 
costs, it is questionable whether autologous tissue 
flaps should be applied when VAC and skin grafting is 
available.
Adjuvant chemoradiotherapy
Due to the extremely small number and emergent 
presentation, there are no studies and recommen-
dations as to when to start this form of therapy 
after complex surgical treatment of rectal cancer-
induced FG. Only two articles mentioned adjuvant 
chemoradiotherapy after initial colostomy - an 
insufficient pool of data for making conclusions[47,63]. 
If oncologically indicated, it should be offered when all 
wounds have healed completely. If flaps were used, 
consultation with a plastic/reconstructive surgeon is 
advisable.
PROGNOSIS
All-cause FG
The mortality from all-cause FG has dropped signi-
ficantly in the last century. In 1871, Jones claimed 46% 
mortality for all NSTIs. Unfortunately, mortality has 
changed little since Meleney in 1924 first recognized the 
need for early surgical intervention[154]. Currently, the 
survival rate is in the range of 60% to even 100% (Table 
1). Since many studies were conducted on males, the 
difference in male-female survival is unknown.
There are several issues here. First, mostly all-
cause FG survival or mortality is reported. Second, 
reports are from different decades. Third, the specific 
underlying cause is not always presented and 
prognosis could be etiology dependent. Fourth, non-
catastrophic soft tissue infections are sometimes 
defined as FG, declaring a better prognosis falsely. 
Fifth, when true FG is present, the underlying cause 
is sometimes not attributed correctly due to the 
confounding factors[155].
Poor prognostic factors include age over 60, 
peripheral vascular disease, poor nutritional status[1], 
sepsis[84], positive blood cultures[84] and delayed 
presentation/treatment[156]. The duration of symptoms 
is prognostic and none of the patients admitted within 
48 hours of symptom onset died[1,35]. Female pelvic 
anatomy has been claimed to be better for drainage 
of secretions through the vagina[157]. On the other 
hand, some suggested that it is a disadvantage 
related to rapid dissemination of the disease[158,159]. 
Other poor prognostic parameters include high 
serum creatinine, lactate, sodium and calcium or low 
bicarbonate[160,161], low magnesium at admission[162] 
and renal function impairment on admission[12,163,164]. 
Increased serum calcium may be due to renal failure, 
bacteremia or TPN. Lactate level > 4.0 mmol/L is an 
independent predictor of mortality[165]. High neutrophil-
lymphocyte ratio and the platelet-lymphocyte ratio 
values were associated with significant increases in 
the number of debridements, hospital stay duration, 
cost and mortality rate[23]. The influence of diabetes 
mellitus[12,25,166-169] on mortality is controversial but the 
extent to the abdominal wall has been reported to be 
directly related to mortality[1,12,170,171]. The involved body 
surface area (BSA) and the number of debridements 
did not predict the outcome in some series[66,167,169]. 
In contrast, BSA ≥ 15 cm2 had a mortality of 75%[24]. 
Therefore, this issue remains controversial[161,163,168,169].
mean age, race, the prevalence of comorbid 
conditions and number of debridements were similar 
in both genders. However, twice as many women 
required mechanical ventilation and dialysis with longer 
hospital stay and mortality but without statistical 
significance[10]. Table 1 shows the average duration of 
hospitalization in all-cause FG of 24 d (range 1 to 278 d). 
Of all the anaerobic species isolated in all-cause FG, 
none was present as the sole organism. No differences 
in clinical course, morbidity or mortality were 
demonstrated with different bacteria(s) isolated[172-174].
Prognostic indices for mortality predictions such 
as Fournier’s Gangrene Severity Index (FSGI) are still 
controversial[24,175,176]. many studies show significant 
mortality with FSGI > 9% and 100% mortality with 
FSGI > 11[35,167,177]. Some claim usefulness in predicting 
survival but not the length of hospital stay[137]. Of 
the nine parameters of FSGI, temperature, heart 
rate and respiratory rate were considered to be the 
most important[1]. APACHE Ⅱ score correlated with 
the prognosis with a significant increase in mortality 
with a score over 25[178]. Other indices include age-
adjusted Charlson Comorbidity Index (ACCI)[179] and 
the surgical Apgar Score (sAPGAR)[180], which are easily 
calculated at the bedside but the prognostic power is 
controversial[181].
Anorectal causes of FG
The disease usually behaves more aggressively, 
produces severe systemic toxicity and is associated with 
higher mortality than FG from other causes[68,94,156,182]. 
The survival of female patients is 71%[29]. Survival 
varied from 0% to 85.7% and was presented in only 
four articles (Table 1). The real incidence and prognosis 
of any specific cause cannot be calculated from the 
available data.
One of the inaccuracies with previously mentioned 
indices is that these do not evaluate the influence 
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of the underlying cause on prognosis, duration of 
hospitalization, number of debridements or other 
parameters. It was previously stated that different 
primary locations and causes (could) have different 
prognoses. Yilmazlar et al[183] modified FGSI, adding 
the dissemination score (plus age), making the Uludag 
FSGI (UFGSI) for all-cause FG.
Rectal cancer-induced FG
Rectal cancers that spontaneously perforate without the 
development of FG seem to be much more aggressive 
than rectal cancer in general as a significantly larger 
proportion of these patients have metastatic disease 
at the time of diagnosis (64% vs 29%). Survival in 
patients with locally contained perforated rectal cancer 
is very much dependent on the presence of metastatic 
disease. In the absence of the latter, if a wide margin 
clear of all macroscopic tumor is achieved, the survival 
curve approximates that of patients with a non-
perforated tumor[184].
Duration of hospitalization cannot be obtained for 
disease-specific or even etiology group-specific FG 
(Table 1). Duration of hospitalization of rectal cancer-
induced FG ranges from 23-130 d. Unfortunately, only 
30% of cases have these data (Table 3). None of the 
articles presented BSA and correlation with survival 
could not be made (Table 3).
FSGI was calculated in only one of 23 rectal cancer-
induced FG cases and no other scoring systems were 
used or have data for calculations (Table 3). The 
overall prognosis is as follows: survival 74%, mortality 
13% and for 13% there was no data (Table 3).
There are many limitations in these studies for 
final conclusions. First, long-term follow-up is lacking. 
Therefore, only prognosis of FG (due to rectal cancer), 
not the prognosis of rectal cancer itself after surviving 
FG, is known. Long-term survival is unknown because 
less than 50% of surviving patients had follow-up 
for one year or more (Table 3). Second, prognostic 
comparison between T4 rectal cancer, perforated rectal 
cancer and rectal cancer-induced FG groups considering 
long-term survival cannot be made. The presumption is 
that the prognosis of rectal cancer-induced FG could be 
worse due to: (1) significant delay in starting adjuvant 
chemoradiotherapy in survivors; and (2) inflammation 
due to perforation of rectal cancer aids in spreading or 
promoting cancer cell dissemination. Third, analysis 
of the influence of the type of surgical procedure is 
insufficient due to the rarity of this pathology and 
(potentially) low rate of published cases that did not 
survive any form of surgical treatment. In the group 
that underwent APR, whether as an initial operation 
(13%) or delayed after colostomy (26%), survival was 
100%. Hartmann’s procedure as the initial operation 
was performed in 8.7% with the survival of 100% 
(Table 3). On the contrary, the survival with only a loop 
colostomy was 80% (Table 3). Conclusions cannot be 
drawn because there is no possibility of comparison. 
Therefore, patients with the more advanced disease, 
poor general status, older age or hemodynamic 
instability could be offered only colostomy. Finally, 
it is important to emphasize that all patients that 
underwent rectal cancer resection survived.
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